Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | OGA | O60502 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 2/20 | 0.31 |
| ▸ | TK2 | O00142 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12541692 | 0.87 | HIF1A (0.33) | GRIN2BHIF1AOGAADRB1DNMT1 | |
| SCHEMBL11442293 | 0.78 | KDM4E (0.47) | HIF1ALMNASMN1; SMN2 | |
| SCHEMBL17824385 | 0.77 | GRIN2B (0.41) | GRIN2B | |
| SCHEMBL17825952 | 0.76 | CSF1R (0.43) | LMNATP53 | |
| SCHEMBL17825943 | 0.74 | TSHR (0.50) | HIF1ALMNASMN1; SMN2TP53RXFP1 | |
| SCHEMBL17825908 | 0.73 | SLC28A2 (0.44) | LMNASMN1; SMN2TP53HTT | |
| SCHEMBL17826004 | 0.73 | CDC7 (0.49) | — | |
| SCHEMBL3790076 | 0.72 | HSD17B10 (0.38) | HIF1ALMNATP53HTT | |
| SCHEMBL1047109 | 0.71 | ADRB1 (0.33) | HIF1AOGAADRB1DNMT1LMNA | |
| SCHEMBL1262483 | 0.71 | PNP (0.44) | ADRB1DNMT1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6958318-B2 | Recombinant bacterial cells for delivery of PNP to tumor cells | THE UAB RESEARCH FOUNDATION (US) | 2005-10-25 | — | — | US | claimed |
| US-20030077268-A1 | Recombinant bacterial cells for delivery of PNP to tumor cells | THE UAB RESEARCH FOUNDATION | 2003-04-24 | — | — | US | claimed |
| EP-0715523-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | UAB RESEARCH FOUNDATION (US) | 2002-12-18 | — | — | EP | claimed |
| US-6491905-B1 | GENETIC VECTORS COMPRISING DNA SEQUENCE CODES FROM ESCHERICHIA PURINE NUCLEOSIDE PHOSPHORYLASE (PNP), USED AS ANTICARCINOGENS IN COMBINATION WITH PURINE ANALOGUES AS PRODRUGS; GENE THERAPY | THE UAB RESEARCH FOUNDATION | 2002-12-10 | — | — | US | claimed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | claimed |
| US-5552311-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | claimed |
| EP-0715523-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1995007718-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1995-03-23 | — | — | WO | claimed |
| US-11020416-B2 | Cancer chemotherapy employing halogenated analogs of thymidine | ORDAHL CHARLES (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190247412-A1 | CANCER CHEMOTHERAPY EMPLOYING HALOGENATED ANALOGS OF THYMIDINE | ORDAHL CHARLES (US) | 2019-08-15 | — | — | US | disclosed |
| US-10278983-B2 | Cancer chemotherapy employing halogenated analogs of thymidine | ORDAHL CHARLES (US) | 2019-05-07 | — | — | US | disclosed |
| EP-1430123-B1 | A METHOD FOR GENERATING HYPERMUTABLE ORGANISMS | UNIV JOHNS HOPKINS (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170216338-A1 | CANCER CHEMOTHERAPY EMPLOYING HALOGENATED ANALOGS OF THYMIDINE | ORDAHL CHARLES (US) | 2017-08-03 | — | — | US | disclosed |
| WO-2016154013-A1 | CANCER CHEMOTHERAPY EMPLOYING HALOGENATED ANALOGS OF THYMIDINE | ORDAHL CHARLES (US) | 2016-09-29 | — | — | WO | disclosed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | disclosed |
| US-5945100-A | Tumor delivery vehicles | FBP CORPORATION (US) | 1999-08-31 | — | — | US | disclosed |
| US-5552311-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| US-5552311-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0715523-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1996-06-12 | — | — | EP | disclosed |
| WO-1995007718-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1995-03-23 | — | — | WO | disclosed |